Jonathan Chapman Appointed as President and CEO of PTS Diagnostics

Aerobiotix Raises $25M Growth Equity Financing Led by Global Healthcare Investment Firm Vivo Capital

The new funding will be used to accelerate sales, marketing, and new product development.

Aurora Spine Receives IRB Approval: To Commence Registration for Multicenter Study of its SiLO™ Device for SI Joint Pain

“This registry aims to provide interventional pain physicians in the United States with clinical data that supports the safety and effectiveness of the SiLO sacroiliac fixation technique. I am excited to be part of the study and to train others so that we can continue to advance therapies that relieve pain and restore function,” said Jack Diep, M.D., a Pain Medicine Specialist in Lake Havasu City, AZ.

Jonathan Chapman brings 20 years of leadership experience in the medical device industry, most recently serving as President of ARKRAY USA, Inc. He joins PTS Diagnostics with an accomplished track record regarding mergers and acquisitions, post-acquisition integration, global product launches, market identification, and strategic positioning.

I’m honored to join the PTS Diagnostics team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes and assessment of cardiovascular disease risk,” said Jonathan Chapman, President and CEO of PTS Diagnostics. “We will continue our legacy of bringing leading innovation to patients across the globe. PTS Diagnostics’ broad capabilities, world-class leadership team, and committed people give me great confidence about our future.”

Mr. Chapman received a Bachelor of Arts from Sheffield University UK, LLM Commercial and Corporate Law from University of London (SOAS) and LLM Health Law from Hamline Law School, St. Paul, MN. PTS Diagnostics is confident that his international experience will be immensely valuable when leading the organization across global markets.

Mr. Chapman will be based out of the Whitestown, Ind. global headquarters.

As a comprehensive point-of-care diagnostics company, PTS Diagnostics manufactures solutions that close gaps in care for patients with chronic conditions such as diabetes, cardiovascular disease, and other related comorbidities.

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine

Related Articles